摘要:

TIA-1 is a monoclonal antibody (mAb) that identifies cytolytic cells. We studied eleven B cell non-Hodgkin's lymphomas (NHL) of low grade, eleven B cell NHL of intermediate-high grade, and 10 benign lymphoid hyperplasias (BLH) to investigate potential differences in the number of host cytolytic tumor infiltrating lymphocytes (TILs). Frozen sections were immunostained with TIA-1 mAb and the number of immunoreactive cells (TIA-1+) per mm2of tissue was quantitated within reactive or neoplastic lymphoid follicles or random areas of diffuse NHL. The number of TIA-1 + cells/mm2was significantly higher in intermediate and high grade B cell NHL than in low grade NHL or BLH with means±se of 1377.8±173, 866.2±92.3 and 774.1±76.2, respectively (p<0.0183 and p<0.0125). There was no significant difference between BLH and low grade NHL.The increased number of TIA-1 + TILs in B cell NHL of intermediate and high grade suggests the possibility of a host cytolytic immune response versus the tumor. Paradoxically, B cell tumors of worst biological outcome contained more cytolytic TILs. Functional defects of host cytolytic TILs in NHL patients should be investigated in future studies.

ISSN:1042-8194    

DOI:10.3109/10428199309148509

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP 1) is expressed in Hodgkin and Reed-Sternberg (HRS) cells in about one half of Hodgkin's disease (HD) cases. In vitro, LMP 1 induces B-cell expression of CD23 antigen, ICAM-1 and LFA-3. To evaluate the influence of LM P 1 on the expression of these molecules in HRS cells in vivo, we performed a quantitative frozen section immunohistological study comparing the numerical density (cells per unit area) of HRS cells expressing the CD23 antigen, ICAM-1 and LFA-3 in 14 LMP 1-positive and 13 LMP 1-negative HD cases. CD23 antigen was demonstrated in HRS cells in five LMP 1-positive and three LMP 1-negative cases (not significant). The relative density of HRS cells tended to be lower in the LMP 1-positive than in the LMP 1-negative cases, but this did not reach significance (0.2>2p>0.1). All recognizable HRS cells expressed ICAM-1 and LFA-3 irrespective of LMP 1 status. We conclude that expression of CD23 antigen and LMP 1 are not coordinated in HD. Although LMP 1 may have some influence on CD23 antigen expression, it is unlikely that the latter is of importance in the putative EBV induced growth transformation of HRS cells in vivo.

ISSN:1042-8194    

DOI:10.3109/10428199309148510

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

We report the immunohistologic and the genotypic analysis of lymph node biopsies from 23 cases of reactive processes, and two cases of atypical lymphoproliferations (AL). Clonal gene rearrangements were detected in 5 cases of proven reactive processes as well as in both AL, in which no signs of malignancy were detected during the phenotypic analysis. No patient, apart from the two AL cases, showed any progression to malignancy during a follow-up period of 28–43 months after the initial biopsy.

ISSN:1042-8194    

DOI:10.3109/10428199309148511

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

A simple clinical method is described whereby significant neutropenia and/or thrombocytope-nia following chemotherapy may be predicted in the majority of those patients who receive cytotoxic drugs for lymphomas, and who have normal blood counts at the time of treatment.

ISSN:1042-8194    

DOI:10.3109/10428199309148512

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4×106U/m2IFN alfa-2b initially. After achievement of hématologic remission, the individually minimum effective dose was used for maintenance. There was no response in acute phase disease. Of the 48 patients with chronic phase disease, 22 achieved a hématologic remission (HR), 13 a partial HR (PHR), and 13 did not respond (NR) to IFN. No major cytogenetic response occurred in these patients, but two patients achieved a major molecular response in Southern blots, whereas PCR tests were positive. In a further randomized study, CML patients without prior therapy were treated initially with 4×106U/m2IFN alpha alone (arm A) or in combination with 50μg IFN gamma (arm B). For maintenance, the maximum tolerable dose of IFN alpha was given (up to 10×106U/day). Thirteen patients in arm A (54%) and 14 (56%) patients in arm B achieved a HR, 7 patients (29%) in arm A and 6 patients (24%) in arm B a PHR. No response could be induced in 4 patients (17%) of arm A and 5 patients (21%) of arm B. Major cytogenetic responses were observed in 5 (20%) patients of arm A and 5 patients (20%) of arm B. Major molecular responses were observed in 3 patients of arm A and 5 patients of arm B. A single negative PCR in a sample of one patient from arm A was followed by a molecular relapse without recurrence of disease. A significant advantage of the combination could not be substantiated. The study had to be terminated because of two deaths in arm B probably due to cumulative toxicity of the different IFNs. In study III, all patients were pretreated and received a combination of IFN alpha and IFN gamma following the protocol of study II, arm B. Here, HRs occurred in 15 patients (54%), PHRs in 7 (25%), and 6 patients (21%) were NR. No complete cytogenetic response was achieved in 16 evaluable patients, but major molecular responses were demonstrated in samples of 2 patients. One patient had a negative PCR result at a single time point.

ISSN:1042-8194    

DOI:10.3109/10428199309148513

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Cerebrospinal fluid thymidine kinase (CSF-TK) was measured at diagnosis in 62 patients with acute lymphoblastic leukemia (ALL) without initial neurological manifestations, who achieved a complete remission after chemotherapy. During the follow-up period, 10 patients developed central nervous system (CNS) involvement. At the onset of the disease mean CSF-TK levels in these subjects were found to be significantly higher than those observed in patients without subsequent CNS complications. In particular, 7/10 (70%) of these patients who presented CSF-TK levels above the upper limit of normal (1.4U/μ1) had evidence of a neurological relapse, while 49/52 (94.2%) of subjects with presenting CSF-TK levels of up to 1.4 U/μl did not develop a neurological leukemic disease (p<0.00001). The white blood cell count at diagnosis was significantly increased, but not directly correlated to CSF-TK levels, in the group with CNS involvement, while age, serum thymidine kinase levels and lactic dehydrogenase, FAB classification or immunophenotype were not different in patients with or without neurological relapse. In conclusion, increased levels of CSF-TK at presentation correlate with a high risk of subsequent CNS involvement in patients with responsive ALL.

ISSN:1042-8194    

DOI:10.3109/10428199309148514

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

In the light of recent observations reporting that B-lymphocytic leukemia (B-CLL) cells may express a variety of myelomonocytic antigens, 28 patients with B-CLL and B-leukemic lymphocytic lymphoma were studied for the presence of these antigens using monoclonal antibodies to detect CD13, CD33, CD15 and CD14. Analysis of immunofluorescence (IF) was carried out by two procedures; one which employed the standard conventional method of gating used in our laboratory for flow cytometry, while the other procedure increased the sensitivity of the analysis, by moving the marker for IF to the left, so as to widen the gate to include more cells with low IF.Using the conventional methodology, the mean proportion of cells considered positive was less than 3% for any of the 4 markers studied. In only a few patients were 5% or more of the B-CLL cells positive for some of the markers studied (3 patients with 6.2–11.3% CD13 + 2 with 6.0–9.6% CD14 +, and one with 11.8% CD15 + cells). No case had more than 2.5% + CD33+ cells.The second procedure with a wider gate to enhance sensitivity for less positive cells, increased the number of positive cells for any of the markers in only 4 patients. These results are contradictory to others reported recently, and some of the possible causes for this discrepancy are discussed. It is suggested that more useful data may be obtained if the level of staining intensity and patterns of positive staining are documented in the future.

ISSN:1042-8194    

DOI:10.3109/10428199309148515

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

B cell chronic lymphocytic leukemia (B-CLL) is a disease characterized by an accumulation of monoclonal lymphocytes of B cell origin. Although the neoplastic process involves the B lymphocyte compartment, phenotypic and functional defects within the T lymphocyte population implicate their possible role in the pathogenesis of the disease. We analyzed the functional and morphological integrity of T lymphocytes from the peripheral blood of 64 patients with B-CLL. The activation of B-CLL T cells after PHA stimulation was determined by measuring [3H]-thymidine incorporation, assessing cell numbers in parallel cultures, and by monitoring the lymphocyte subsets during 9 days of cultivation. Our results indicate the presence of three functionally different populations of T cells in the peripheral blood of B-CLL patients. We present evidence for an increased proliferative potential of T lymphocytes from a group of patients with B-CLL.

ISSN:1042-8194    

DOI:10.3109/10428199309148516

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Bryostatin-1 (Bryo), a macrocyclic lactone of the sea water bryozoanBugula neritina, is a potent activator of protein kinase C and was found to exhibit antineoplastic activity in several systems. We studied the effect of Bryo on differentiation and growth modulation of human myeloid leukemia cell lines and freshly explanted blood cells from patients with myeloid leukemia. Alterations at the molecular level and phenotypic changes triggered by Bryo were similar, but not identical, to those induced by phorbol esters. Bryo was able to inhibit cellular proliferation as evidenced by [3H]-thymidine uptake and induced morphological changes associated with monocytic differentiation. In studies using continuous cell lines, the glucocorticoid dexamethasone was unable to prevent the Bryo-induced growth inhibition or the induced phenotypic changes. However, in fresh myeloid Blood cells dexamethasone attenuated these Bryo-triggered effects. Our own data taken together with reports from the literature reviewed here suggest the following conclusions: (i) Bryo, while lacking tumor promoting activity, is able to induce differentiation in maturation arrested leukemia cells; (ii) it exhibits selective antiproliferative properties in normal or malignant hematopoietic cells and supports growth of multipotent stem cells. These features might qualify Bryostatin-1 as a potential candidate for promising research and possibly for future clinical applications.

ISSN:1042-8194    

DOI:10.3109/10428199309148517

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Autoimmune haemolytic anaemia (AIHA) is a frequent complication of chronic lymphocytic leukaemia (CLL). The course of AIHA in CLL is quite variable and unpredictable. We report 9 patients who showed three distinct clinical patterns. Three patients had a single episode of AIHA which responded rapidly to oral prednisolone. Three others had a relapsing course often associated with a rising lymphocyte count which responded to a combination of prednisolone and cytotoxic drugs. The remaining three patients showed very little response to either form of treatment and continued to have haemolytic anaemia for the remainder of their lives. Development of AIHA did not appear to be associated with any particular stage of the disease and only patients with the third type of AIHA seemed to have a short survival.

ISSN:1042-8194    

DOI:10.3109/10428199309148518

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor